Please assess the completion status of the following clinical trial:

Trial Title: ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults~* First kidney transplantation~* No anti HLA immunization prior transplantation~* A risk of DGF higher than 40% calculated by the score DGFS (DGFS \>= 0.4)~* Written informed consent~Exclusion Criteria:~* Previous or combined other transplantations~* Non heart beating donors~* Living donors~* Pre-emptive transplantation~* Patients on peritoneal dialysis~* Leucopenia lower than 3000/mm3~* Thrombopenia lower than 100 000/mm3~* Donor EBV positive / recipient EBV Negative~* Pregnant or lactating women~* Patients under guardianship~* Previous and current history of cancer and/or lymphoma~* Current history of HCV or HBV or HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATG (Type: EXPERIMENTAL): The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery).
- Basiliximab (Type: ACTIVE_COMPARATOR): The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).